Form D · Pharmaceuticals
Esanex, Inc.
Indianapolis, IN · CIK 0001531658
Offering snapshot reported Apr 10, 2017 · SEC filing
- Reported sold
- $2.58M Offering amount: $2.9M
- Investors reported
- 4 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Mar 27, 2017 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Apr 10, 2017 | Initial | $2,584,161 | No comparison | 4 | SEC filing |
| Dec 12, 2012 | Amendment | $15,500,000 | $10,899,998vs Apr 26, 2012 | 4 | SEC filing |
| Jun 13, 2012 | Amendment | $4,753,336 | $153,334vs Apr 26, 2012 | 4 | SEC filing |
| Apr 26, 2012 | Initial | $4,600,002 | No comparison | 3 | SEC filing |
Offering details
- Securities
- Equity, Option to acquire, Security to be acquired
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-284386
Source: Form D, filed Apr 10, 2017. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Steven E Hall | Director, Executive |
| Paul Howard | Director |
| Richard Kent | Director |
| Richard Miller | Director |
| S Edward Torres | Executive |
Issuer details
Industry: Pharmaceuticals (See others in industry)
Address:
115 W. Washington St. Suite 1680 South
Indianapolis, IN, 46204
Indianapolis, IN, 46204